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Abstract 
Cellular differentiation and development appears as a unidirectional process to specific cell fates irreversibly. Once 
differentiated, mature cells seems permanently locked into the differentiated state and unable to return to 
pluripotent stem cell state. However, using cell reprogramming methods it is possible to do reversal cell fate from 
a mature differentiated state to an undifferentiated state or directly to that of progenitors or mature cells of a 
different cell type. This is due to the resetting of the somatic cell specific epigenotype to the pluripotential cell 
specific epigenotype. Different methods are used to reprogram somatic cells into pluripotent cells. Among which 
are somatic cell nuclear transfer, cell fusion, genetic integration of cells extracts into chromatin and direct 
reprogramming using transcription factor integration. These methods result in morphological and molecular 
changes because of modification in chromatin and gene expression. The integration of the genome can be 
performed by the help of viral and non-viral vectors which have great variability the integration efficiency. 
Reprogrammed induced Pluripotent stem cells (iPS) and the recent induced endodermal cells are a few cell types 
to mention. Though these cells have numerous limitation in cell transplantation therapy but are promising cell for 
diseases modeling, drug discovery and bio-artificial organ synthesis. The major problems observed is retaining 
somatic cell genetic memory. Generally it is possible to reprogram personalized cells using different methods so 
that it can be patient specific.  
Keywords: pluripotent, reprogramming, stem cell, transcription factors, vectors.  
 
INTRODUCTION 
Stem cells are the special primordial structures in the body that retain two distinctive properties: the ability to self-
renew and differentiate into a specific cell type (Pera et al., 2000). Based on their differentiation potential stem 
cells can be categorized as totipotent, pluripotent, multipotent, oligopotent and unipotent cells. The commitment 
is more specified as it goes from multipotent cells down to oligopotent and unipotent cells (Odorico et al., 2001). 
Cellular differentiation and development was described as a “one way process” like a ball rolling towards 
different one-way ramified valleys to specific cell fates irreversibly (Waddington, 1957). But in-vitro studies 
shows the presence of plasticity to erase epigenetic barriers using different technical approaches. As a result cells 
can re-acquire their pluripotency through a process, known as “reprogramming” (Campbell, 1996; Wilmut et al., 
1997).In reprogramming it is possible to create pluripotent cell using two different ways: pluripotent 
reprogramming and lineage reprogramming. In the former case the entire developmental process is reversed, and 
a differentiated cell is returned to a pluripotent state (Yu, 2007) whereas in the later, conversion happens directly 
to another mature cell (Orkin and Zon, 2008). In contrary a normal development process, a pluripotent cell (e.g: 
embryonic stem cell) goes to all possible developmental paths and differentiates into a mature cell (Waddington, 
1957). 
Transcription factors and culture medium are the two most important cell fate determinants. This was 
shown to reprogram adult fibroblasts to pluripotent state using TF based technology. It was done by using mouse 
embryonic cells and adult fibroblasts, transduced with retroviral vectors encoding for Oct4, Sox2, Klf4 and cMyc. 
This phenomenon erased epigenetic state and re-established the pluripotent state, named as induced pluripotent 
stem cells (iPSCs) (Takahashi and Yamanaka, 2006).This induced pluripotent stem cells (iPS) are identical to ES 
cells and have the ability to become every cell type in the mammalian body (Shevchenko et al., 2009). Another 
recent study showed also using the idea of linage reprogramming it is possible to create a transdifferentaited 
personalized pluripotent cells  called induced Endodermal progenitor cells (iENDO) cells from human multipotent 
adult progenitor cells (Fanos et al., 2015). Therefore, the objective of this review paper is to highlight the different 
techniques of cell reprogramming as well as the application of reprogrammed cells. 
 
METHODS OF CELL REPROGRAMMING 
Cell reprogramming is a forced method by which morphological and molecular changes that happen as a result of 
modification in chromatin and gene expression. This is due to the resetting of the somatic cell specific epigenotype 
to the pluripotential cell epigenotype. In epigenetic landscape the normal development of cell is a one way process 
from the totipotent cells down to the determined cell population where as in the reprogramming (lineage and 
pluripotent) process somatic cells erases the epigenetic memory and shifted back to the pluripotent 
state(Waddington, 1957) (A), (Yu et al., 2007; Orkin and Zon, 2008) (Figure 1).  
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Figure 1. Schematic diagrams of development and reprogramming of cells in the epigenetic landscape. Adapted 
from: (Waddington, 1957) (A), (Yu et al., 2007) (B), (Orkin and Zon, 2008) (C).  
Traditionally there are different methods by which somatic cells could be reprogrammed into pluripotent 
cells. Among which are somatic cell nuclear transfer, cell fusion, genetic integration of various factors into 
chromatin or direct reprogramming (Do and Scholer, 2006; Hochedlinger and Jaenisch, 2006). 
 
Somatic Cell Nuclear Transfer  
Generation of reprogrammed cells through nuclear transfer has been documented in mouse models (Agarwal, 2006; 
Beyhan et al., 2007; Campbell et al., 2007). The nuclear DNA of somatic cells is transplanted into the enucleated 
oocyte leading to union of both components and then initiated for embryonic development. After maintaining the 
pre-implanted embryo in a culture media finally the developed embryo is transferred to a foster mother (Fulka et 
al., 2004). The aim of method is to generate stem and progenitor cells that are not committed to a specific lineage 
(Jaenisch et al., 2004). 
As a result of inefficient number of available unfertilized oocytes and ethical concern, this technique has 
not been demonstrated in humans. Apart from these, it is also dependent upon voluntary donation of oocytes and 
the efficiency of this technique is also low (Byrne et al., 2007). In general, nuclear transfer (Figure 2) involves two 
steps: The first one is  de-differentiation of a somatic donor cell to an embryonic state and the in vitro maturation 
till the blastocyst stage (also known as therapeutic cloning); The other one is  further development of the cloned 
blastocyst, after the implantation in the maternal uterus (reproductive cloning) (Egli, 2007). 
 
Figure 2. SCNT, Therapeutic and Reproductive cloning. Adapted from: (Egli, 2007) 
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Cell Fusion  
Somatic cells and pluripotent embryonic stem cells go through cell fusion to generate reprogrammed cells (Figure 
3). The cytoplasm of embryonic stem cells contains reprogramming factors which can alter the epigenetic state of 
a somatic cell into a pluripotent cell being fused with a somatic cell (Flasza et al., 2003; Tada et al., 1997). 
In cell fusion, two cells can be fused together by using polyethylene glycol (PEG) to generate a single 
pluripotent cell. The more dividing or the larger cell type is the “dominant” one and the “recessive” cell will 
convert its gene expression profile to the one imposed by the dominant cell type (Yamanaka, 2010). Hybrid cells 
generated have exhibited properties similar to embryonic stem cells. These cells expressed reactivated pluripotent 
markers like Oct4, Sox2 and Nanog (Cowan et al., 2005; Do and Scholer, 2004) (Figure 3). 
 
Figure 3. Reprogramming by Cell fusion. Adapted from: (Ying et al., 2002) 
 
Reprogramming Through Cell Extracts  
The process of reprogramming somatic cells by this method involves the exposure of differentiated cells or nuclei 
to cell- extracts made from mammalian embryonal carcinoma or ES cells (Han et al., 2010; Neri et al., 2007).It 
involves the reversible permeabilisation of differentiated cells using the chemical streptolysin- O (SLO), followed 
by exposure to cell extracts and has been shown to partially reprogram the treated cells towards an embryonic state, 
mainly in transformed and immortalized cell lines (Walev et al., 2001). 
 
Direct Reprogramming 
By using viral or non-viral vector transcription factors are introduced into somatic cells to generate pluripotent 
stem cells. The field jumpstarted in 2006 when Takahashi and Yamanaka demonstrated that the overexpression of 
pluripotency-related transcription factors (TFs) into induced pluripotent stem cells (iPSCs) from adult fibroblasts 
which is strongly resemble ESCs. The use of different “cocktails” of transcription factors (TFs) allows not only to 
redirect fibroblasts to an ESC-fate but also to a lineage-specific cell types/precursors, from a different tissue 
(Asuelime, 2012). Creation of iPS cells has paved a way to reprogram a cell in its somatic state back to its 
pluripotent state which might be used for disease modeling, drug screening and patient-specific cell therapy 
(Amabile and Meissner, 2009) (Figure 4).Mouse embryonic and adult fibroblasts, transduced with retroviral 
vectors encoding for Oct4, Sox2, Klf4 and c-Myc and cultured in ESC-medium, erased their differentiated 
epigenetic state and re-established the pluripotent state; these cells were named induced pluripotent stem cells 
(iPSCs) (Takahashi and Yamanaka, 2006). 
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Figure 4. iPSC technology and applications. Adapted from: (Takahashi and Yamanaka, 2006) 
 
VECTORS IN CELL REPROGRAMMING  
There are a number of different approaches to transduce reprogramming factors into somatic cells that can affect 
the efficiency of reprogramming and the quality of resultant cells (Wernig et al., 2007). Retroviral vectors were 
used in reprogramming of somatic cells, but nowadays different methods allows the generation of cells like iPSCs. 
These vectors are generally categorized into two major groups as: integrative and non-integrative methods. 
Integrative methods are more efficient than non-integrative methods, but are less safe than non-integrative methods 
(Gonzalez et al., 2011; Okita et al., 2011). 
 
Integrative Vectors 
Retrovirus is a DNA based integrative vector and is the original method of reprogramming by transduction of TFs 
(Oct4, Sox2, Klf4, and c-myc) (Takahashi and Yamanaka, 2006). This vector system, allows the cloning of large 
number of DNA fragments more efficiently and are generally silenced in pluripotent cells, but only infect dividing 
cells (Hotta and Ellis, 2008). Lentivirus is another integrative DNA based vector which is more preferable than 
retrovirus vector as it can infect both non-dividing and proliferative cells but, it is less efficient than retrovirus 
(Papapetrou et al., 2009). 
 
Non-Integrative Vectors 
The major weakness of reprogramming strategies by retrovirus and lentivirus is the integration of viral vectors 
into host chromosomes. Integration can cause insertional mutagenesis, interference with gene transcription, 
genome instability and induce malignant transformation (Nakagawa et al., 2008).  
None DNA based, replication-incompetent vectors are Adenoviruses are used to allow the transient 
expression of exogenous genes without integration into the host genome, but less efficient than integrating vectors. 
Although this is less efficient, when compared to integrative vectors it appears to be an excellent expression vehicle 
for generating reprogrammed cells, because it is a non-integrating virus (Stadtfeld et al., 2008; Zhou and Freed, 
2009). 
Sendaivirus has been widely studied as an efficient expression vector and is known to effectively express 
transgene without integration (Armeanu, 2003; Bernloehr et al., 2004). A Sendaivirus vector carrying the four TFs 
(Oct4, Sox2, Klf4 and c-myc) is sufficient to successfully generate iPS colonies. Even though it does not integrate 
into the genome, the persistence of a viral genome within iPS clones  and requirement of many passages (18-20) 
to degrade induced pluripotent stem cells remains a concern for downstream applications (Fusaki, 2009).  
Episomal factors, allow for the introduction of genetic factors without integration into the host genome. 
A lack of host genome integration inherently removes the risk of random transgene reactivation associated with 
viral vectors (Okita et al., 2008). As plasmids are a well-developed technology and are very easy to generate them 
in a large quantity in the laboratory and have a relatively low cost-of-use compared to viral vectors (Yu, 2009). 
Although plasmids are desirable vectors for reprogramming, their efficacy remains well below that of viral 
integration, limiting the potential for large scale cell reprogramming using plasmids. This reduced efficacy be due 
to the temporary nature of plasmids and the speculated ongoing nature of the reprogramming process transcription 
factor expression may be reduced before the iPS reprogramming process is complete. This resulted in altering the 
stoichiometric balance of factors and ending reprogramming (Okita and Yamanaka, 2011). For liposomal 
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magnetofection (LMF), cationic lipids mediate the self-assembly of complexes containing plasmids and 
nanoparticles of super paramagnetic iron. These “CombiMag-DNA” ternary complexes can be concentrated at cell 
surfaces using a strong magnetic field to transfect vectors into the targeted cells (Park et al., 2012). 
Modified mRNAs transcribing for the four TFs (Oct4, Sox2, Klf4 and cMyc) are capable of 
reprogramming when passed into the cytosol of various human cell types with a catatonic delivery vehicle (Warren, 
2010). Initially, cytotoxicity of transfected mRNAs inhibited effective reprogramming, requiring modifications to 
the mRNA. This was modified the ribonucleotide bases of the vector mRNAs by substituting 5-methylcytidine for 
cytidine and pseudouridine for uridine resulting in reducing the immunogenicity of the mRNAs (Rosa and 
Brivanlou, 2010) (Figure 5).  
 
Figure 5. Schematic displaying of the various reprogramming strategies used in generation of reprogrammed cells 
(iPSCs). Adapted from: (Anokye-Danso et al., 2011). 
 
APPLICATIONS OF REPROGRAMMED CELLS 
The development of induced pluripotent stem cell (iPSC) has created new avenues in basic research for disease 
modeling, drug discovery, screening, bio-artificial organ synthesis and cell transplantation therapy (Takahashi and 
Yamanaka, 2006). This is discussed as follows. 
 
Disease Modeling 
Accurate disease modeling is a biotechnological problem of fundamental importance. Most current disease models 
rely upon murine model organisms, which are capable of providing insight, but are less than ideal due to 
interspecies differences. iPSC technology could allow for in vitro disease modeling, using cultures isolated from 
those suffering with a given condition. If widely applied, patient specific iPS cultures could potentially be created 
to analyze the nuances of a disease in a particular patient, determining which course of treatment would be best 
(Saha and Jaenisch, 2009). 
An attractive feature of iPS cells is the ability to derive them from adult patients to study the cellular basis 
of disease as it provides pathophysiological course of the disease. Since iPS cells are self-renewing and pluripotent, 
they represent unlimited source of patient-derived cells which can be turned into any type of cell in the body. iPS 
cells have been generated for a wide variety of human genetic diseases (Park et al., 2008; Freedman et al., 2013). 
In many instances, the patient-derived iPS cells exhibit cellular defects not observed in iPS cells from healthy 
patients, providing insight into the pathophysiology of the disease (Grskovic et al., 2011). 
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Drug Discovery and Screening  
Reprogrammed cells (iPSCs) also has a promising research application for drug discovery. Developing new drugs 
is exceedingly expensive and many drug candidates are rejected in the final human trial stage due to toxicology 
concerns (Nsair and MacLellan, 2011; Rubin, 2008). If drugs could have been screened for toxicology earlier in 
the development cycle and eliminated earlier, allowing for increased funding to more promising drugs (figure 6). 
For example; using iPS cell it is possible to harvest cells from patients afflicted with certain diseases in culture for 
drug testing without risking potentially life-threatening side effects in the patient (Wu and Hochedlinger, 2011). 
In addition, using iPS cells for drug screening should save a lot of money because the costs associated with raising 
and caring for laboratory research animals would be greatly reduced or eliminated (Wu and Hochedlinger, 2011). 
 
Figure 6. Drug discovery and toxicology workflow. Somatic cells are isolated from a broad cross section of donors, 
reprogrammed, and differentiated into relevant tissues for toxicology screening and drug testing. Adapted from: 
(Rubin, 2008). 
 
Bio-Artificial Organ Synthesis and Cell Therapy 
Human ‘liver buds’ (iPSC-LBs) were grown from a mixture of three different kinds of stem cells: hepatocytes (for 
liver function) coaxed from iPSCs; endothelial stem cells (to form lining of blood vessels) from umbilical cord 
blood; and mesenchymal stem cells (to form connective tissue). This allowed different cell types to self-organize 
into a complex organ, mimicking the process in fetal development. After growing in vitro for a few days, the liver 
buds were transplanted into mice where the ‘liver’ quickly connected with the host blood vessels and continued to 
grow. Most importantly, it performed regular liver functions including metabolizing drugs and producing liver-
specific proteins. Further studies will monitor the longevity of the transplanted organ in the host body (ability to 
integrate or avoid rejection) and whether it will transform into tumors (Baker and Monya, 2013; Takebe et al., 
2013  
Diseases causing destruction of specific cell type present needs use of cell therapy. In the future, 
treatments or cures for these diseases could involve differentiating a patient’s iPS cells into the specific cell types 
and reintroducing them into the patient to restore the original function of the missing cells (Wu and Hochedlinger, 
2011). 
 
LIMITATIONS OF REPROGRAMMED PLURIPOTENT CELLS 
Although recent research has made clear regarding the potential application of iPSCs in translational medicine, 
there are certain limitations associated with the reprogramming of adult somatic cells. The lack of efficient 
differentiation (Hu et al., 2010) and the risk of genetic instability (Laurent et al., 2011) were among the challenges. 
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Reprogrammed cells by SCNT has also limitations; it involves manipulation of pre-implanted embryos 
and therefore raise serious legal and ethical issues (Camporesi, 2007). The scarcity of fresh donated mature human 
oocytes of high quality available for research is another significant obstacle of SCNT (Hall et al., 2007). The 
efficiency of the overall cloning process is quite low as the majority of embryos derived from animal cloning do 
not survive after implantation (Solter, 2000). 
 
CONCLUSION AND RECOMMENDATIONS 
The concept of reprogramming mature cells in to a pluripotent stem cell state is a paradigm shifting discovery. 
Understanding of reprogramming pathways helps the development of autologous cellular therapies for the 
treatment of numerous diseases and the improved efficiency of animal-based biotechnology. Strategies such as 
nuclear transfer and induced reprogramming have been used to induce somatic cells into an embryonic-like 
pluripotent state. The discovery of iPSC and its technology boosted the stem cell field in that it allows to obtain 
pluripotent stem cells for autologous therapy, drug discovery, disease modeling and bio-artificial organ synthesis. 
Problems of immune rejection as well as the ethical issues related to the use of human embryo for scientific 
purposes was avoided in these cell category. At present, there still remains a risk of teratoma formation in the event 
that a subpopulation of reprogrammed (iPS) cells. Efficiency of reprogrammed (iPS) cell generation remains an 
issue, especially with regards to non-integrated vector technologies. Additionally somatic cell genetic instability 
by retaining genetic memory of their parent cell. Generally it is possible to reprogram personalized cells using 
different methods so that the cell harvested can be patient specific and more stable.  
Based on the above conclusions the following recommendations are forwarded: 
• Detailed studies on cellular and molecular mechanisms that mediate reprogramming, should need further 
investigation to develop practical applications in veterinary and human medicine. 
• For patient-specific autologous treatment using reprogrammed cells, methods should be developed and 
optimized so that cells can be generated in sufficient quantity, reliably and in a time frame appropriate 
for the targeted disease. 
• Pharmaceutical companies should practice stem cells for the toxicological analysis of newly discoverd 
drugs, this can avoid the use of laboratory animal targeted drug discovery. 
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